Arrowhead (ARWR) announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals (IONS) to declare that Ionis’s United States Patent No. 9,593,333 is invalid and not infringed by Arrowhead’s planned commercialization of investigational plozasiran, which is under FDA review. Arrowhead intends to vigorously pursue its claims in this litigation. Ionis has threatened legal action against Arrowhead concerning its plozasiran product, including allegations of infringement of the ‘333 patent. Arrowhead believes those infringement allegations are baseless and is confident it will prove the ‘333 patent is invalid and not infringed. Arrowhead is not seeking monetary relief in this action, but rather a declaratory decree establishing that the ‘333 patent is invalid and/or not infringed by the manufacture, use, sale, or offer for sale of plozasiran.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead requests regulatory clearance to initiate ARO-MAPT clinical trial
- Sarepta price target raised to $15 from $12 at Leerink
- Cautious Optimism: Hold Rating for Arrowhead Pharmaceuticals Amid Novartis Collaboration and Balance Sheet Concerns
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis